Evidence map›Paper›PMID 42519027›Full record

ArticleiScience2026

Multiple genetic engineering of porcine red blood cells improves compatibility with human blood.

Pan Lu, Yong Wang, Jiaxiang Du, Jie Yan, Shaoping Deng, Dongsheng He, Zhipeng Ren, Ziqiang Dai, Dianyuan Li, Dengke Pan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pan LuDepartment of Hepatological Surgery, The People's Hospital of Jianyang City, Jianyang, China.
Yong WangXenotransplantation and Regeneration Key Laboratory of Sichuan Province, Sichuan Clon Organ Biotechnology Co., Ltd., Chengdu, China.
Jiaxiang DuXenotransplantation and Regeneration Key Laboratory of Sichuan Province, Sichuan Clon Organ Biotechnology Co., Ltd., Chengdu, China.
Jie YanXenotransplantation and Regeneration Key Laboratory of Sichuan Province, Sichuan Clon Organ Biotechnology Co., Ltd., Chengdu, China.
Shaoping DengXenotransplantation and Regeneration Key Laboratory of Sichuan Province, Sichuan Clon Organ Biotechnology Co., Ltd., Chengdu, China.
Dongsheng HeDepartment of Cardiac Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Zhipeng RenDepartment of Cardiac Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Ziqiang DaiDepartment of Cardiac Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Dianyuan LiDepartment of Cardiac Surgery, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, China.
Dengke PanXenotransplantation and Regeneration Key Laboratory of Sichuan Province, Sichuan Clon Organ Biotechnology Co., Ltd., Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To address critical challenges in clinical blood shortages and limited preservation periods, particularly affecting emergency transfusions, transgenic pig red blood cells (RBCs) emerge as a promising solution. We performed multi-gene editing on pig RBCs by knocking out three Xeno antigen genes (

Indexed as

genetical modificationhemolytic reactionimmune rejectionXenotransfusion

Identifiers

PMID42519027
PMCPMC13382133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.